# GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

- Link: https://www.directorstalkinterviews.com/gsk-to-acquire-biotech-growth-trust-portfolio-company-nuvalent-for-10-6bn/4121253332
- Published: 2026-06-09T14:29:07+01:00
- Author: Amilia Stone

**Biotech Growth Trust plc** (LON:BIOG) has noted the announcement on Tuesday, 9
June 2026 that [GSK plc](https://www.directorstalkinterviews.com/ftse-company/glaxosmithkline-plc/gsk.l)
has entered into an agreement to acquire BIOG portfolio company, Nuvalent, Inc. 
for $10.6 billion, or $124 per share, in cash, representing a 40% premium to Nuvalent’s
closing price on Monday, 8 June 2026.

Nuvalent is a US-based biopharmaceutical company focused on developing targeted 
therapies for the treatment of cancer. Its two lead drugs are both under review 
for marketing approval and are expected to be available to treat non-small cell 
lung cancer patients that have specific mutations later this year.

The Company’s holdings in Nuvalent represented 1.5% of the Company’s net asset value(
NAV) at the time of the announcement. The transaction will be reflected in the Company’s
NAV as at close of business on Tuesday, 9 June 2026, which will be announced on 
Wednesday, 10 June 2026.

This follows recent acquisitions of portfolio companies Avidity Biosciences, Cidara
Therapeutics, Amicus Therapeutics, Apellis Pharmaceuticals, KalVista Pharmaceuticals
and Esperion Therapeutics.

Share on:
